---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-077564"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:05:30.551366+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotech raises $1.33M via private placement of common stock and warrants

## Summary
- Sold 578,643 shares at $2.295/share with warrants to purchase same number at $2.55.
- Warrants exercisable 6 months after issuance, 5-year term, no price protection.
- Proceeds to fund first third of THIO-101 trial Part C in non-small cell lung cancer.
- Closing expected on or about March 28, 2024, subject to customary conditions.
- Shares and warrants issued as restricted securities under Rule 144.

## SEC filing metadata
- accession: 0001193125-24-077564
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312524077564/0001193125-24-077564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312524077564/d776139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-077564
- JSON: https://secwatch.observer/filing/0001193125-24-077564.json
- Plain text: https://secwatch.observer/filing/0001193125-24-077564.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.33 million (effective 2024-03-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $1.33 million
  - Effective: 2024-03-25
  source text: On March 25, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 578,643 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Warrants ”) to purchase up to 578,643 shares of Common Stock, at a price per share of $2.295, for an aggregate purchase price of approximately $1.33 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312524077564/0001193125-24-077564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.